OTLK Stock — OUTLOOK THERAPEUTICS INC

OUTLOOK THERAPEUTICS INC (OTLK)

Updated October 16, 2026.

OTLK is a Stock. Total return is -99.9% over the past 10.3 years, 433.9 points behind SPY at 334.0%.

Outlook Therapeutics is a clinical-stage biopharmaceutical company developing monoclonal antibody therapies for eye diseases, with its lead candidate ONS-5010 in Phase III trials for wet age-related macular degeneration and other retinal conditions. The company does not currently distribute dividends. This security may appeal to investors seeking exposure to clinical-stage biotech development, though it carries the risks inherent to companies without approved products or established revenue.

OTLK performance versus SPY

Price and return data through 2026-10-16.

Total return is -99.9% over the past 10.3 years, 433.9 points behind SPY at 334.0%. Over the past year its total return — price change plus distributions reinvested — is -63.6%. Its deepest 1-year drawdown was 92.0%.

OTLK key facts

Asset type

Stock

Asset class

Equity

Inception date

06/14/2016

Distribution frequency

None

Last close

$0.49 (as of 2026-10-16)

Market cap

$118,851,096

Average volume

3087236.0

Payment date

03/18/2019

Beta

0.674

Payout ratio

0.0%

Forward P/E

2.8498

EPS

$-0.70

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

OTLK risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 92.0%.

Who may consider OTLK — and who may not

It is a weaker fit for investors who need monthly cash flow (OTLK does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on OTLK

• All tickers starting with O

Tagged: Healthcare.

Frequently asked questions